Gary W. Falk, MD, MS / Ikuo Hirano, MD - Enhancing Outcomes in Adults and Children With Eosinophilic Esophagitis by Targeting Type 2 Inflammation

episode

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NHL Pacific Division Preview 2026 1h 48m · 25 Sep 2026 · The Steve Dangle Podcast

NPR News: 09-24-2026 8PM EDT 4 min · 25 Sep 2026 · NPR News Now

Fletch, Vaughan & Hayley's Lil Bitta Pod - 25th September 2026 7 min · 25 Sep 2026 · ZM's Fletch, Vaughan & Hayley

Send Me To Sleep | Orchards 48 min · 25 Sep 2026 · Send Me To Sleep

Fletch, Vaughan & Hayley's Big Pod - 25th September 2026 1h 27m · 25 Sep 2026 · ZM's Fletch, Vaughan & Hayley

8PM ET 09/24/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

Report any issue

Source

Recorded08 Jun 2023

Publisherc.answersincme.com ↗

Handlerec:13096846

Show notes

Please visit answersincme.com/HQX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of eosinophilic esophagitis (EoE) discuss biologic therapies targeting type 2 inflammation. Upon completion of this activity, participants should be better able to: Identify the role of type 2 inflammation in EoE in the context of treatment implications; and Describe evidence-based strategies to integrate biologics targeting type 2 inflammation into clinical practice for the management of EoE.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in